DE69534656D1 - Gentechnisch manipulierte menschliche kunitz domänen die menschliche neutrophile elastase hemmen - Google Patents

Gentechnisch manipulierte menschliche kunitz domänen die menschliche neutrophile elastase hemmen

Info

Publication number
DE69534656D1
DE69534656D1 DE69534656T DE69534656T DE69534656D1 DE 69534656 D1 DE69534656 D1 DE 69534656D1 DE 69534656 T DE69534656 T DE 69534656T DE 69534656 T DE69534656 T DE 69534656T DE 69534656 D1 DE69534656 D1 DE 69534656D1
Authority
DE
Germany
Prior art keywords
human
elastase
neutrophic
genetically manipulated
kunitz domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69534656T
Other languages
English (en)
Other versions
DE69534656T2 (de
Inventor
Charles Ley
Charles Ladner
Kosow Guterman
Lindsay Roberts
William Markland
Baribault Kent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DE69534656D1 publication Critical patent/DE69534656D1/de
Publication of DE69534656T2 publication Critical patent/DE69534656T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
DE69534656T 1994-12-16 1995-12-15 Gentechnisch manipulierte menschliche kunitz domänen die menschliche neutrophile elastase hemmen Expired - Lifetime DE69534656T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US358160 1994-12-16
US08/358,160 US5663143A (en) 1988-09-02 1994-12-16 Engineered human-derived kunitz domains that inhibit human neutrophil elastase
PCT/US1995/016349 WO1996020278A2 (en) 1994-12-16 1995-12-15 Genetically engineered human-derived kunitz domains that inhibit human neutrophil elastase

Publications (2)

Publication Number Publication Date
DE69534656D1 true DE69534656D1 (de) 2006-01-05
DE69534656T2 DE69534656T2 (de) 2006-08-17

Family

ID=23408531

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69534656T Expired - Lifetime DE69534656T2 (de) 1994-12-16 1995-12-15 Gentechnisch manipulierte menschliche kunitz domänen die menschliche neutrophile elastase hemmen

Country Status (9)

Country Link
US (1) US5663143A (de)
EP (2) EP1734121A3 (de)
JP (1) JP3977419B2 (de)
AT (1) ATE311452T1 (de)
CA (1) CA2207820A1 (de)
DE (1) DE69534656T2 (de)
DK (1) DK0797666T3 (de)
ES (1) ES2255066T3 (de)
WO (1) WO1996020278A2 (de)

Families Citing this family (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5750373A (en) * 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
EP1489097B1 (de) * 1994-01-11 2011-10-19 Dyax Corporation Inhibitoren des Humanplasmins, die sich von den Kunitz Domänen ableiten
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) * 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
HU226419B1 (en) 1996-03-11 2008-12-29 Aerovance Human bikunin
US5985543A (en) 1996-10-11 1999-11-16 The Trustees Of The University Of Pennsylvania Compositions and methods for detection of antibody binding to cells
US5876925A (en) * 1996-10-11 1999-03-02 The Trustees Of The University Of Pennsylvania Magnetically activated cell sorting for production of proteins
EP1005551A2 (de) * 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Inhibitor 3 des gewebefaktor-weges.
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
WO1999063090A2 (en) * 1998-06-03 1999-12-09 Scios, Inc. Protease inhibitor peptides
EP1100890A2 (de) 1998-07-27 2001-05-23 Genentech, Inc. Verbesserung der transformationseffizienz in phagendisplay durch abänderung des hüllproteins
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
DK1374891T3 (da) * 1998-12-22 2009-01-26 Bayer Ag Fremgangsmåde til fremskyndelse af hastigheden af mucociliær clearance
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
CA2393869A1 (en) * 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU2001265154A1 (en) * 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US20020150594A1 (en) * 2000-06-26 2002-10-17 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
ES2296796T3 (es) * 2000-09-04 2008-05-01 Debiopharm S.A. Procedimiento de purificacion de proteinas epi-hne.
EP1184393A1 (de) * 2000-09-04 2002-03-06 Debiopharm S.A. Verfahren zur Reinigung von EPI-HNE Proteinen
EP1201249A1 (de) * 2000-10-31 2002-05-02 Debiopharm S.A. Suspension von EPI-HNE-4, daraus hergestelltes Trockenpulveraerosol, Herstellungsverfahren und Arzneimittel enthaltend diese Suspension- oder Aerosolzubereitung und ihre Verwendung
AU2002217014B2 (en) * 2000-10-31 2006-11-02 Debiopharm S.A. Suspension of an EPI-hNE protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
US20030157561A1 (en) * 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
US20050053973A1 (en) * 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20060223114A1 (en) * 2001-04-26 2006-10-05 Avidia Research Institute Protein scaffolds and uses thereof
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) * 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
PT1390535E (pt) * 2001-04-26 2010-10-04 Amgen Mountain View Inc Bibliotecas combinatórias de domínios monoméricos
US20040175756A1 (en) * 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2451239A1 (en) 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic taget (tat) polypeptides
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
NZ531674A (en) 2001-09-18 2009-03-31 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
AU2003210220A1 (en) * 2002-01-23 2003-09-02 Debiopharm Sa Production of epi-hne-4 comprising reduction of improperly processed form
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
CA2475382A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2528254T3 (es) * 2002-06-07 2015-02-05 Dyax Corp. Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico
WO2004019857A2 (en) * 2002-08-29 2004-03-11 Genentech, Inc. Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
MXPA06000347A (es) 2003-07-08 2006-03-28 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
CA2543360A1 (en) * 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
NZ596981A (en) 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
US20090074843A1 (en) * 2004-03-31 2009-03-19 Flemming Reissig Jensen Use of epi-hne 1-4
EP1789453A2 (de) * 2004-05-18 2007-05-30 Genentech, Inc. Haupthüllproteinvarianten des m13-virus zur c-terminalen und bi-terminalen anzeige eines heterologen proteins
JP2008504916A (ja) * 2004-07-16 2008-02-21 コロプラスト アクティーゼルスカブ 創傷治療具
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
AU2005309722B2 (en) * 2004-11-22 2011-10-20 Dyax Corp. Plasmin-inhibitory therapies
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
BRPI0607985A2 (pt) 2005-03-10 2009-10-27 Genentech Inc modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores
EP1871163A2 (de) 2005-06-06 2008-01-02 Genentech, Inc. Transgene tiermodelle und deren verwendung zur gencharakterisierung
AR054165A1 (es) * 2005-07-13 2007-06-06 Avidia Inc Proteinas de union a il-6
CA2619577A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
GB0521404D0 (en) * 2005-10-20 2005-11-30 Ares Trading Sa Kunitz domain containing protein
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
RU2426742C2 (ru) 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
EP3088522B1 (de) 2005-12-29 2017-11-29 The Regents of the University of California Verfahren und zusammensetzungen in verbindung mit mutanter kunitz-domäne i von tfpi-2
WO2007079096A2 (en) 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2082645A1 (de) 2006-04-19 2009-07-29 Genentech, Inc. Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
US20090142259A1 (en) * 2006-05-12 2009-06-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors
EP2057465A4 (de) 2006-08-09 2010-04-21 Homestead Clinical Corp Organspezifische proteine und anwendungsverfahren dafür
CA2662236A1 (en) 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
NZ584330A (en) * 2007-10-04 2013-01-25 Bionomics Ltd Markers of endothelial cells and uses thereof
CN101186646B (zh) * 2007-10-26 2010-06-09 中国科学院昆明动物研究所 眼镜王蛇毒蛋白酶抑制剂及其衍生物的应用
SI2514436T1 (en) 2007-11-07 2018-04-30 Genentech, Inc. IL-22 for use in the treatment of microbial diseases
CA2728473A1 (en) 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
MX2011006483A (es) 2008-12-16 2011-07-13 Novartis Ag Sistemas de despliegue en levadura.
CN104984319A (zh) 2008-12-19 2015-10-21 巴克斯特国际公司 Tfpi抑制剂和使用方法
EP2385843A4 (de) * 2009-01-06 2013-02-27 Dyax Corp Behandlung von mukositis mit kallikrein-hemmern
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
JP5819308B2 (ja) 2009-10-22 2015-11-24 ジェネンテック， インコーポレイテッド マクロファージ刺激タンパク質のヘプシン活性化を調節するための方法及び組成物
MX338694B (es) 2009-11-30 2016-04-27 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
PT3459564T (pt) * 2010-01-06 2022-01-31 Takeda Pharmaceuticals Co Proteínas de ligação à calicreína plasmática
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
CN102985113B (zh) 2010-02-23 2015-05-20 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
ES2621809T3 (es) 2010-03-19 2017-07-05 Baxalta GmbH Inhibidores de TFPI y procedimientos de uso
KR20130079384A (ko) 2010-05-03 2013-07-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
KR102107695B1 (ko) 2011-01-06 2020-05-07 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CA2831136A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
WO2012142526A1 (en) 2011-04-14 2012-10-18 Modiano Jaime Use of tumor fas expression to determine response to anti-cancer therapy
PE20141693A1 (es) 2011-08-01 2014-11-24 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
BR112014005720A2 (pt) 2011-09-15 2017-12-12 Genentech Inc método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
EP2812350B1 (de) 2012-02-11 2019-04-03 F.Hoffmann-La Roche Ag R-spondin-translokationen und verfahren damit
JP6198807B2 (ja) 2012-03-16 2017-09-20 ジェネンテック， インコーポレイテッド 操作され立体構造的に安定化されたタンパク質
EP2844248A1 (de) 2012-03-16 2015-03-11 F. Hoffmann-La Roche AG Verfahren zur behandlung von melanomen mit pak1-inhibitoren
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
DK2827883T3 (da) 2012-03-21 2019-07-29 Baxalta GmbH Tfpi-inhibitorer og fremgangsmåder til anvendelse
CN106290917B (zh) 2012-04-25 2020-06-05 比奥德赛公司 用于检测蛋白质的变构调节剂的方法
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
KR20200079568A (ko) 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
EP2708235A1 (de) * 2012-09-17 2014-03-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Peptidantagonisten des Vasopressin-2-Rezeptors
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
EP3385277A1 (de) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22-polypeptide und il-22-fc-fusionsproteine sowie verfahren zur verwendung
CA2905123A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
ES2819209T3 (es) 2013-07-16 2021-04-15 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de TIGIT
CA2933881A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
KR20220151005A (ko) * 2014-02-24 2022-11-11 다케다 게엠베하 Uti 융합 단백질
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
MX2016015163A (es) 2014-05-23 2017-03-03 Genentech Inc Biomarcadores mit y metodos para su uso.
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
BR112017000672A2 (pt) 2014-07-15 2017-11-14 Genentech Inc composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
EP3188746B1 (de) 2014-09-05 2024-06-19 The Johns Hopkins University Capn9-aktivität als ziel für eine therapeutische strategie zur behandlung von myofibroblastendifferenzierung und assoziierten erkrankungen
AU2015348657B2 (en) 2014-11-20 2021-06-10 F. Hoffmann-La Roche Ag Combination therapy of T cell activating bispecific antigen binding molecules CD3 ABD folate receptor 1 (FolRl) and PD-1 axis binding antagonists
JP2017537929A (ja) 2014-12-05 2017-12-21 ジェネンテック， インコーポレイテッド Ｐｄ−１軸アンタゴニスト及びｈｐｋ１アンタゴニストを用いたがん治療のための方法及び組成物
EP3237906B8 (de) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
KR102668727B1 (ko) 2015-04-24 2024-05-28 제넨테크, 인크. 다중특이적 항원-결합 단백질
EP3297674B1 (de) 2015-05-22 2023-01-04 Translational Drug Development Llc Benzamid- und wirkstoffzusammensetzungen und verfahren zur verwendung
WO2016205681A1 (en) 2015-06-19 2016-12-22 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
WO2017079442A1 (en) 2015-11-04 2017-05-11 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2017112955A1 (en) 2015-12-23 2017-06-29 Pharma Llc Moonshot Methods for inducing an immune response by inhibition of nonsense mediated decay
US11246868B2 (en) 2016-04-26 2022-02-15 Icahn School Of Medicine At Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CN110198729A (zh) 2016-09-09 2019-09-03 豪夫迈·罗氏有限公司 卷曲蛋白的选择性肽抑制剂
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
EP3544601B1 (de) 2016-11-23 2024-03-20 Translational Drug Development, LLC Eine zusammensetzung, die ein benzamid und einen tnfrsf-agonisten umfasst, der an 4-1bb oder gitr bindet, und die verwendung derselben bei der behandlung von krebs.
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
SG10202111663PA (en) 2017-02-27 2021-12-30 Regeneron Pharma Humanized model of kidney and liver disorders
PE20200150A1 (es) 2017-04-21 2020-01-17 Genentech Inc Uso de antagonistas de klk5 para el tratamiento de una enfermedad
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
EP3728321A1 (de) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Verwendung von pilra-bindenden mitteln zur behandlung einer erkrankung
AU2020257270A1 (en) 2019-04-17 2021-11-18 Impossible Foods Inc. Materials and methods for protein production
JP7397884B2 (ja) 2019-05-09 2023-12-13 ジェネンテック， インコーポレイテッド 抗体の作製方法
AU2020281535A1 (en) 2019-05-24 2022-01-27 Merck Patent Gmbh Combination therapies using CDK inhibitors
TW202142562A (zh) 2020-03-05 2021-11-16 美商迪亞醫藥美國公司 烏司他丁多肽
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US20210338833A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
CN116685325A (zh) 2020-10-20 2023-09-01 豪夫迈·罗氏有限公司 Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
WO2022118197A1 (en) 2020-12-02 2022-06-09 Pfizer Inc. Time to resolution of axitinib-related adverse events
CN112940095B (zh) * 2021-02-07 2022-04-15 西南大学 家蚕BmSPI51突变蛋白BmSPI51M及其制备方法和应用
TW202313045A (zh) 2021-06-09 2023-04-01 瑞士商赫孚孟拉羅股份公司 用於癌症治療之組合療法
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114332T1 (de) * 1989-05-13 1994-12-15 Bayer Ag Proteinaseninhibitoren, verfahren zu ihrer herstellung sowie diese enthaltende arzneimittel.
US5409895A (en) * 1990-11-13 1995-04-25 Mochida Pharmaceutical Co., Ltd. Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
ATE431364T1 (de) * 1991-03-01 2009-05-15 Dyax Corp Inhibitoren der menschlichen elastase von neutrophilen
WO1993009233A2 (en) * 1991-10-31 1993-05-13 The Salk Institute Biotechnology/Industrial Associates Inc. Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
IL104314A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3570558B2 (ja) * 1993-05-01 2004-09-29 持田製薬株式会社 Ｄｎａ断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法
EP1489097B1 (de) * 1994-01-11 2011-10-19 Dyax Corporation Inhibitoren des Humanplasmins, die sich von den Kunitz Domänen ableiten
EP0827539A2 (de) * 1995-05-08 1998-03-11 Scios Inc. Protease inhibitoren vom kunitz-type

Also Published As

Publication number Publication date
EP0797666B1 (de) 2005-11-30
WO1996020278A3 (en) 1996-10-24
JPH10510996A (ja) 1998-10-27
ES2255066T3 (es) 2006-06-16
DE69534656T2 (de) 2006-08-17
WO1996020278A2 (en) 1996-07-04
US5663143A (en) 1997-09-02
EP1734121A2 (de) 2006-12-20
DK0797666T3 (da) 2006-04-03
EP0797666A2 (de) 1997-10-01
JP3977419B2 (ja) 2007-09-19
CA2207820A1 (en) 1996-07-04
EP1734121A3 (de) 2008-09-10
ATE311452T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DE69534656D1 (de) Gentechnisch manipulierte menschliche kunitz domänen die menschliche neutrophile elastase hemmen
DK0643608T3 (da) Proteinrensning
DE69517196D1 (de) Inhibitoren der menschlichen neutrophilenelastase
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
DE59010884D1 (de) Mutanten von humanem Antithrombin III
ES2117624T3 (es) Peptidos anticoagulantes.
ES2060689T3 (es) Alcoholes peptidicos anticoagulantes.
DK0443429T3 (da) Stabiliserede sulfonater og sulfater af hirudin
ATE177432T1 (de) Antikoagulierende peptide
ES2094228T3 (es) Peptidos anticoagulantes.
ES2108010T3 (es) Peptidos que bloquean la union de las celulas a la s-laminina.
NO944025L (no) Forbedret fremstilling av rekombinant protein
DE69003306D1 (de) Reinigung von Proteinhydrolysaten.
ES2076238T3 (es) Adnc que codifica la proteina 9 de placenta (pp9), su aislamiento y utilizacion.
ITRM920517A1 (it) Procedimento di produzione della proteina sv-iv ricombinante e proteina sv-iv ricombinante.
MX9203296A (es) Proteinas bmp-7.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition